Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Firefly Neuroscience (AIFF) EBT (2016 - 2025)

Firefly Neuroscience has reported EBT over the past 15 years, most recently at -$2.5 million for Q4 2025.

  • Quarterly results put EBT at -$2.5 million for Q4 2025, up 34.47% from a year ago — trailing twelve months through Dec 2025 was -$19.9 million (down 90.07% YoY), and the annual figure for FY2025 was -$19.9 million, down 90.07%.
  • EBT for Q4 2025 was -$2.5 million at Firefly Neuroscience, up from -$2.6 million in the prior quarter.
  • Over the last five years, EBT for AIFF hit a ceiling of $456438.0 in Q2 2023 and a floor of -$12.9 million in Q1 2025.
  • Median EBT over the past 5 years was -$1.2 million (2022), compared with a mean of -$2.0 million.
  • Biggest five-year swings in EBT: surged 314.36% in 2021 and later plummeted 3851.17% in 2022.
  • Firefly Neuroscience's EBT stood at -$2.4 million in 2021, then soared by 57.39% to -$1.0 million in 2022, then fell by 4.32% to -$1.1 million in 2023, then tumbled by 251.58% to -$3.8 million in 2024, then soared by 34.47% to -$2.5 million in 2025.
  • The last three reported values for EBT were -$2.5 million (Q4 2025), -$2.6 million (Q3 2025), and -$1.8 million (Q2 2025) per Business Quant data.